COVID-19 vaccine hesitancy in Africa: a call to action

Mutombo, Polydor Ngoy; Fallah, Mosoka; Munodawafa, Davison; Kabel, Ahmed M.; Houéto, David; Goronga, Tinashe; Mweemba, Oliver; Balance, Gladys; Onya, Hans; Kamba, Roger S; Chipimo, Miriam; Kayembe, Jean-Marie Ntumba; Akanmori, Bartholomew D.

doi:10.1016/s2214-109x(21)00563-5

Cited by 118 publications

(123 citation statements)

References 5 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“… 16 While vaccine uptake is high in many regions of low and middle income countries, complex social factors drive hesitancy for some communities. For example, “a history of colonial medical and vaccine research abuse in Africa diminishes trust in current vaccines.” 17 Scarcity and unpredictability of vaccine supply also complicated building vaccine confidence. 17 18 19 …”

Section: What Caused Global Vaccine Inequity?mentioning

confidence: 99%

See 1 more Smart Citation

It is not too late to achieve global covid-19 vaccine equity

Yamey

Garcia

Hassan

et al. 2022

BMJ

View full text Add to dashboard Cite

show abstract

Section: What Caused Global Vaccine Inequity?mentioning

confidence: 99%

“…For example, “a history of colonial medical and vaccine research abuse in Africa diminishes trust in current vaccines.” 17 Scarcity and unpredictability of vaccine supply also complicated building vaccine confidence. 17 18 19 …”

Section: What Caused Global Vaccine Inequity?mentioning

confidence: 99%

It is not too late to achieve global covid-19 vaccine equity

Yamey

Garcia

Hassan

et al. 2022

BMJ

View full text Add to dashboard Cite

show abstract

“…We welcome Bernard Seytre's engagement with our Comment. 1 However, his response leaves us more perplexed than enlightened. It is not clear whether Seytre is questioning the sources or disputing the facts.…”

mentioning

confidence: 99%

Misunderstanding poor adherence to COVID-19 vaccination in Africa – Authors' reply

Mutombo

Fallah

Munodawafa

et al. 2022

The Lancet Global Health

Self Cite

View full text Add to dashboard Cite

“…Adverse events after vaccination have become a challenge; myocarditis and pericarditis are frequently reported following receipt of messenger RNA (mRNA) vaccines, including BNT162b2 (Pfizer vaccine) and mRNA-1273 (Moderna vaccine) and neurological AEs have also been reported [ 13 ]. In Africa, the low vaccine coverage and the common vaccine hesitancy undermine efforts to fight the COVID-19 pandemic [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey

et al. 2022

View full text Add to dashboard Cite

The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection ( p = 0.19) or AEs post-vaccine ( p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination. Supplementary Information The online version contains supplementary material available at 10.1007/s00296-022-05130-3.

show abstract

COVID-19 vaccine hesitancy in Africa: a call to action

Cited by 118 publications

References 5 publications

It is not too late to achieve global covid-19 vaccine equity

It is not too late to achieve global covid-19 vaccine equity

Misunderstanding poor adherence to COVID-19 vaccination in Africa – Authors' reply

Rheumatologists’ knowledge and perception of COVID-19 and related vaccines: the vaXurvey2 online survey

Contact Info

Product

Resources

About